The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today

Group 1 - Alpine Immune Sciences received a $4.9 billion buyout offer from Vertex Pharmaceuticals following positive Phase 2 results for its autoimmune drug Povetacicept, which is set to enter Phase 3 trials for a rare kidney disease [1] - Alpine's stock surged by 21% on April 10 and an additional 36% overnight, opening at $64.18 per share on April 11 [1] - Vertex aims to expand its immunology portfolio with Povetacicept, which Vertex CEO described as a "pipeline-in-a-product," indicating potential for testing in other conditions [2] Group 2 - Alpine reported that its Phase 2 trial costs exceeded expectations, ending 2023 with $44 million in cash from a total of $327 million in cash and securities, alongside a negative operating cash flow of $79 million [2] - Vertex is competing with other pharmaceutical companies in the immunology sector, with increased spending from competitors like Johnson & Johnson, AbbVie, Bristol Myers Squibb, and Sanofi [2] - Vertex's market capitalization is approximately $102 billion, with 2023 revenues around $10 billion, including a net income of $3.6 billion [2]